AngioDynamics (ANGO) Reports In-Line Q4 EPS, Offers FY22 Guidance

AngioDynamics (NASDAQ: ANGO) reported Q4 EPS of $0.00, in-line with the analyst estimate of $0.00. Revenue for the quarter came in at $76.8 million versus the consensus estimate of $72.68 million.

GUIDANCE:

AngioDynamics sees FY2022 EPS of $0.00-$0.05, versus the consensus of $0.05. AngioDynamics sees FY2022 revenue of $305-310 million, versus the consensus of $286.7 million.

For earnings history and earnings-related data on AngioDynamics (ANGO) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• General Mills (GIS) Tops Q4 EPS by 14c, Beats on Revenue; Offers FY27 EPS Guidance
• Concentrix Corporation (CNXC) Misses Q2 EPS by 1c; Guides lower than expectations